Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

The combination of an increasing prevalence of diabetes and the aging of populations enables the appearance of a greater number of associated complications such as diabetic retinopathy. Diabetic retinopathy is the leading cause of preventable vision loss in working-age adults. The objective of this Special Issue is to highlight the existing evidence regarding the relationship between oxidative stress and low-grade chronic inflammation induced by hyperglycemia with the development and progression of diabetic retinopathy, with an emphasis on the importance of early diagnosis and the use of antioxidant and anti-inflammatory approaches to prevent or delay the harmful effects of diabetes on retinal tissue.

Medicine --- eicosanoids --- oxidative stress --- diabetic retinopathy --- cyclooxygenase --- lipoxygenase --- Cytochrome P450 --- HDAC6 --- tubastatin A --- retinal endothelial cells --- retinal endothelial cell senescence --- db/db mice --- Cinnamomi Ramulus --- Paeoniae Radix --- CPA4-1 --- blood-retinal barrier --- occludin --- human retina --- epiretinal membrane --- internal limiting membrane --- vitreoretinal surgery --- macular hole --- proliferative diabetic retinopathy --- antioxidants --- diabetes mellitus --- free radicals --- high-mobility group box 1 (HMGB1) --- inflammatory pathways --- novel therapies --- diabetic retinopathy (DR) --- inflammation --- angiogenesis --- extracellular vesicles --- miRNA --- biomarkers --- apoptosis --- fenofibrate --- thioredoxin --- hyperglycemia --- astaxanthin --- carotenoid --- reactive oxygen species --- photoreceptor cells --- PI3K --- Nrf2 --- eicosapentaenoic acid (EPA) --- docosahexaenoic acid (DHA) --- retinal pigment epithelium --- antioxidant --- ascorbic acid --- retinal disease --- vitamin D --- GLP-1 --- superoxide dismutase --- biomarkers of diabetic retinopathy --- metabolic memory --- tear film --- aqueous humor --- vitreous humor --- mitochondria --- redox --- photoreceptor --- glycation --- aging --- glyoxalase --- n/a

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

The combination of an increasing prevalence of diabetes and the aging of populations enables the appearance of a greater number of associated complications such as diabetic retinopathy. Diabetic retinopathy is the leading cause of preventable vision loss in working-age adults. The objective of this Special Issue is to highlight the existing evidence regarding the relationship between oxidative stress and low-grade chronic inflammation induced by hyperglycemia with the development and progression of diabetic retinopathy, with an emphasis on the importance of early diagnosis and the use of antioxidant and anti-inflammatory approaches to prevent or delay the harmful effects of diabetes on retinal tissue.

Medicine --- eicosanoids --- oxidative stress --- diabetic retinopathy --- cyclooxygenase --- lipoxygenase --- Cytochrome P450 --- HDAC6 --- tubastatin A --- retinal endothelial cells --- retinal endothelial cell senescence --- db/db mice --- Cinnamomi Ramulus --- Paeoniae Radix --- CPA4-1 --- blood-retinal barrier --- occludin --- human retina --- epiretinal membrane --- internal limiting membrane --- vitreoretinal surgery --- macular hole --- proliferative diabetic retinopathy --- antioxidants --- diabetes mellitus --- free radicals --- high-mobility group box 1 (HMGB1) --- inflammatory pathways --- novel therapies --- diabetic retinopathy (DR) --- inflammation --- angiogenesis --- extracellular vesicles --- miRNA --- biomarkers --- apoptosis --- fenofibrate --- thioredoxin --- hyperglycemia --- astaxanthin --- carotenoid --- reactive oxygen species --- photoreceptor cells --- PI3K --- Nrf2 --- eicosapentaenoic acid (EPA) --- docosahexaenoic acid (DHA) --- retinal pigment epithelium --- antioxidant --- ascorbic acid --- retinal disease --- vitamin D --- GLP-1 --- superoxide dismutase --- biomarkers of diabetic retinopathy --- metabolic memory --- tear film --- aqueous humor --- vitreous humor --- mitochondria --- redox --- photoreceptor --- glycation --- aging --- glyoxalase

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

The use of lipid-based nanosystems, including lipid nanoparticles (solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC)), nanoemulsions, and liposomes, among others, is widespread. Several researchers have described the advantages of different applications of these nanosystems. For instance, they can increase the targeting and bioavailability of drugs, improving therapeutic effects. Their use in the cosmetic field is also promising, owing to their moisturizing properties and ability to protect labile cosmetic actives. Thus, it is surprising that only a few lipid-based nanosystems have reached the market. This can be explained by the strict regulatory requirements of medicines and the occurrence of unexpected in vivo failure, which highlights the need to conduct more preclinical studies.Current research is focused on testing the in vitro, ex vivo, and in vivo efficacy of lipid-based nanosystems to predict their clinical performance. However, there is a lack of method validation, which compromises the comparison between different studies.This book brings together the latest research and reviews that report on in vitro, ex vivo, and in vivo preclinical studies using lipid-based nanosystems. Readers can find up-to-date information on the most common experiments performed to predict the clinical behavior of lipid-based nanosystems. A series of 15 research articles and a review are presented, with authors from 15 different countries, which demonstrates the universality of the investigations that have been carried out in this area.

Technology: general issues --- nanostructured lipid carriers (NLC) --- formulation optimization --- rivastigmine --- quality by design (QbD) --- nasal route --- nose-to-brain --- N-alkylisatin --- liposome --- urokinase plasminogen activator --- PAI-2 --- SerpinB2 --- breast cancer --- liposomes --- target delivery nanosystem --- FZD10 protein --- colon cancer therapy --- supersaturation --- silica-lipid hybrid --- spray drying --- lipolysis --- lipid-based formulation --- fenofibrate --- mesoporous silica --- oral drug delivery --- hyaluronic acid --- drug release --- light activation --- stability --- mobility --- biocorona --- dissolution enhancement --- phospholipids --- solid dosage forms --- porous microparticles --- nanoemulsion(s) --- phase-behavior --- DoE --- D-optimal design --- vegetable oils --- non-ionic surfactants --- efavirenz --- flaxseed oil --- nanostructured lipid carriers --- nanocarrier --- docohexaenoic acid --- neuroprotection --- neuroinflammation --- fluconazole --- Box‒Behnken design --- nanotransfersome --- ulcer index --- zone of inhibition --- rheological behavior --- ex vivo permeation --- nanomedicine --- cancer --- doxorubicin --- melanoma --- drug delivery --- ultrasound contrast agents --- phospholipid coating --- ligand distribution --- cholesterol --- acoustic response --- microbubble --- lipid phase --- dialysis --- ammonia --- intoxication --- cyanocobalamin --- vitamin B12 --- atopic dermatitis --- psoriasis --- transferosomes --- lipid vesicles --- skin topical delivery --- oligonucleotide --- self-emulsifying drug delivery systems --- hydrophobic ion pairing --- intestinal permeation enhancers --- Caco-2 monolayer --- clarithromycin --- solid lipid nanoparticles --- optimization --- permeation --- pharmacokinetics --- follicular targeting --- dexamethasone --- alopecia areata --- lipomers --- lipid polymer hybrid nanocapsules --- biodistribution --- skin --- ethyl cellulose --- n/a

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Mounting evidence suggests a bidirectional relationship between metabolism and inflammation. Molecular crosstalk between these processes occurs at different levels with the participation of nuclear receptors, including peroxisome proliferator-activated receptors (PPARs). There are three PPAR isotypes, α, β/δ, and γ, which modulate metabolic and inflammatory pathways, making them key for the control of cellular, organ, and systemic processes. PPAR activity is governed by fatty acids and fatty acid derivatives, and by drugs used in clinics (glitazones and fibrates). The study of PPAR action, also modulated by post-translational modifications, has enabled extraordinary advances in the understanding of the multifaceted roles of these receptors in metabolism, energy homeostasis, and inflammation both in health and disease. This Special Issue of IJMS includes a broad range of basic and translational article, both original research and reviews, focused on the latest developments in the regulation of metabolic and/or inflammatory processes by PPARs in all organs and the microbiomes of different vertebrate species.

nuclear receptor --- gene transcription --- inflammation --- molecular docking --- PPARβ/δ --- lung --- pulmonary artery --- GW0742 --- GSK3787 --- docking --- lipopolysaccharide (LPS) --- PPARγ ligand --- coumarin --- fluorescent ligand --- screening --- crystal structure --- PPAR --- atopic dermatitis --- psoriasis --- metabolic reprograming --- glucose --- fatty acids --- mycobacteria --- M. tuberculosis --- M. leprae --- PPARs --- lipid droplets --- metabolic alterations --- hepatic damage --- nuclear factors --- pharmacological targets --- AMPK --- GDF15 --- insulin resistance --- type 2 diabetes mellitus --- peroxisome proliferator-activated receptor gamma (PPARγ) --- real-time PCR --- ELISA --- immunohistochemistry --- signaling pathway --- PPAR gamma --- brain --- neural stem cells --- infection --- neuroinflammation --- HIV --- Zika --- cytomegalovirus --- neurogenesis --- microglia --- liver damage --- toll-like receptor 4 --- P2Y2 receptor --- metabolic syndrome --- resveratrol --- quercetin --- PPARα --- peroxisome --- β-oxidation --- PPRE --- ligand --- coregulator --- micronutrients --- PPARα knockout --- adipose tissue --- browning --- lipid metabolism --- depression --- PPARg --- neuropathology --- corticotropin releasing hormone --- norepinephrine --- subgenual prefrontal cortex --- amygdala --- nucleus accumbens --- common carotid artery occlusion --- electroretinography --- fibroblast growth factor 21 --- pemafibrate --- peroxisome proliferator-activated receptor alpha --- retinal ischemia --- skeletal muscle --- substrate metabolism --- nonalcoholic fatty liver disease (NAFLD) --- sex dimorphism --- lipidomics --- hepatic sex-biased gene expression --- PPARγ --- pulmonary arterial hypertension --- TGFβ --- vascular injury --- proliferation --- kidney fibrosis --- pattern-recognition receptors --- phagocytosis --- nitric oxide synthase --- fenofibrate --- oleoylethanolamide --- palmitoylethanolamide --- cancer --- immunity --- obesity --- diabetes --- miRNA --- DNA methylation --- histone modification --- peroxisome-proliferator-activated receptor --- fatty acid oxidation --- doping control --- regulatory T cells --- exercise --- nuclear receptors --- nutrigenomics --- energy homeostasis --- dairy animals --- non-alcoholic fatty liver disease (NAFLD) --- non-alcoholic steatohepatitis (NASH) --- peroxisome proliferator-activated receptors (PPAR) --- bezafibrate --- fenofibric acid --- peroxisome proliferator-activated receptor --- dual/pan agonist --- X-ray crystallography --- n/a

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Mounting evidence suggests a bidirectional relationship between metabolism and inflammation. Molecular crosstalk between these processes occurs at different levels with the participation of nuclear receptors, including peroxisome proliferator-activated receptors (PPARs). There are three PPAR isotypes, α, β/δ, and γ, which modulate metabolic and inflammatory pathways, making them key for the control of cellular, organ, and systemic processes. PPAR activity is governed by fatty acids and fatty acid derivatives, and by drugs used in clinics (glitazones and fibrates). The study of PPAR action, also modulated by post-translational modifications, has enabled extraordinary advances in the understanding of the multifaceted roles of these receptors in metabolism, energy homeostasis, and inflammation both in health and disease. This Special Issue of IJMS includes a broad range of basic and translational article, both original research and reviews, focused on the latest developments in the regulation of metabolic and/or inflammatory processes by PPARs in all organs and the microbiomes of different vertebrate species.

Research & information: general --- Biology, life sciences --- Biochemistry --- nuclear receptor --- gene transcription --- inflammation --- molecular docking --- PPARβ/δ --- lung --- pulmonary artery --- GW0742 --- GSK3787 --- docking --- lipopolysaccharide (LPS) --- PPARγ ligand --- coumarin --- fluorescent ligand --- screening --- crystal structure --- PPAR --- atopic dermatitis --- psoriasis --- metabolic reprograming --- glucose --- fatty acids --- mycobacteria --- M. tuberculosis --- M. leprae --- PPARs --- lipid droplets --- metabolic alterations --- hepatic damage --- nuclear factors --- pharmacological targets --- AMPK --- GDF15 --- insulin resistance --- type 2 diabetes mellitus --- peroxisome proliferator-activated receptor gamma (PPARγ) --- real-time PCR --- ELISA --- immunohistochemistry --- signaling pathway --- PPAR gamma --- brain --- neural stem cells --- infection --- neuroinflammation --- HIV --- Zika --- cytomegalovirus --- neurogenesis --- microglia --- liver damage --- toll-like receptor 4 --- P2Y2 receptor --- metabolic syndrome --- resveratrol --- quercetin --- PPARα --- peroxisome --- β-oxidation --- PPRE --- ligand --- coregulator --- micronutrients --- PPARα knockout --- adipose tissue --- browning --- lipid metabolism --- depression --- PPARg --- neuropathology --- corticotropin releasing hormone --- norepinephrine --- subgenual prefrontal cortex --- amygdala --- nucleus accumbens --- common carotid artery occlusion --- electroretinography --- fibroblast growth factor 21 --- pemafibrate --- peroxisome proliferator-activated receptor alpha --- retinal ischemia --- skeletal muscle --- substrate metabolism --- nonalcoholic fatty liver disease (NAFLD) --- sex dimorphism --- lipidomics --- hepatic sex-biased gene expression --- PPARγ --- pulmonary arterial hypertension --- TGFβ --- vascular injury --- proliferation --- kidney fibrosis --- pattern-recognition receptors --- phagocytosis --- nitric oxide synthase --- fenofibrate --- oleoylethanolamide --- palmitoylethanolamide --- cancer --- immunity --- obesity --- diabetes --- miRNA --- DNA methylation --- histone modification --- peroxisome-proliferator-activated receptor --- fatty acid oxidation --- doping control --- regulatory T cells --- exercise --- nuclear receptors --- nutrigenomics --- energy homeostasis --- dairy animals --- non-alcoholic fatty liver disease (NAFLD) --- non-alcoholic steatohepatitis (NASH) --- peroxisome proliferator-activated receptors (PPAR) --- bezafibrate --- fenofibric acid --- peroxisome proliferator-activated receptor --- dual/pan agonist --- X-ray crystallography